Evolent Health, Inc. (NYSE: EVH) general counsel Jonathan Weinberg sold 28,000 shares of the company in a transaction dated Wednesday, September 29. The stock was sold for an average price of $ 28.22, for a total value of $ 790,160.00. The transaction was disclosed in a document filed with the SEC, accessible through this link.
Jonathan Weinberg also recently completed the following transactions:
- On Tuesday August 10, Jonathan Weinberg sold 8,254 Evolent Health shares. The stock was sold for an average price of $ 24.01, for a total value of $ 198,178.54.
NYSE EVH shares traded up $ 0.97 during trading on Friday, reaching $ 31.97. The company had a trading volume of 1,391,464 shares, compared to an average volume of 592,576. The company’s fifty-day moving average price is $ 24.70 and its 200-day moving average price is 21.88. $. Evolent Health, Inc. has a 12-month low of $ 9.44 and a 12-month high of $ 31.97. The stock has a market cap of $ 2.79 billion, a P / E ratio of -37.88 and a beta of 2.40. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt ratio of 0.34.
Evolent Health (NYSE: EVH) last released its quarterly results on Wednesday, August 4. The tech company reported ($ 0.06) EPS for the quarter, beating analyst consensus estimates of ($ 0.11) by $ 0.05. Evolent Health recorded a negative return on equity of 3.38% and a negative net margin of 7.28%. The company posted revenue of $ 222.06 million for the quarter, compared to analysts’ estimates of $ 216.97 million. As a group, stock analysts predict that Evolent Health, Inc. will post earnings per share of -0.27 for the current year.
Large investors have recently changed their positions in the company. Dark Forest Capital Management LP acquired a new position in shares of Evolent Health in the second quarter valued at approximately $ 127,000. Harbor Investments Inc. acquired a new position in Evolent Health shares during the first quarter valued at approximately $ 141,000. SeaCrest Wealth Management LLC acquired a new position in shares of Evolent Health in the second quarter valued at approximately $ 208,000. AlphaCrest Capital Management LLC acquired a new position in shares of Evolent Health in the second quarter valued at approximately $ 213,000. Finally, Teacher Retirement System of Texas acquired a new position in the shares of Evolent Health in the second quarter valued at approximately $ 214,000. 94.50% of the shares are currently held by institutional investors.
A number of research companies have weighed in on EVH. Zacks Investment Research downgraded Evolent Health from a “buy” rating to a “wait” rating in a Wednesday, August 11 research note. Piper Sandler raised its price target on Evolent Health from $ 29 to $ 30.00 and gave the company an “overweight” rating in a research report on Thursday, August 5. TheStreet downgraded Evolent Health from a “d” rating to a “c-” rating in a report released on Monday, August 23. BTIG Research raised its price target on Evolent Health from $ 30.00 to $ 35.00 and gave the stock a “buy” rating in a report released on Monday, September 13. Finally, Canaccord Genuity raised its price target on Evolent Health from $ 24.00 to $ 27.00 and gave the stock a “buy” rating in a report released Thursday, August 5. Two investment analysts rated the stock with a conservation rating and four issued a buy rating for the company’s stock. According to data from MarketBeat.com, Evolent Health currently has an average rating of “Buy” and an average price target of $ 28.40.
About progressive health
Evolent Health, Inc is engaged in the provision of healthcare delivery and payment services. It deals with population health management, administration of health plans and third parties, network performance management and pharmaceutical benefits, risk adjustment, analysis and monitoring. ‘improved performance, as well as the integration of technology and electronic medical records.
Recommended Story: Trading Options – What Is A Throttling?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Evolent Health now?
Before you consider Evolent Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Evolent Health was not on the list.
While Evolent Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here